CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lyra Therapeutics, Inc. - LYRA CFD

0.38
0%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close N/A
Open N/A
1-Year Change N/A
Day's Range N/A
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 17, 2024 0.38 -0.01 -2.56% 0.39 0.39 0.38
May 7, 2024 0.41 0.00 0.00% 0.41 0.46 0.40
May 6, 2024 0.50 0.12 31.58% 0.38 0.61 0.37
May 3, 2024 3.99 -0.65 -14.01% 4.64 4.69 3.91
May 2, 2024 4.59 -0.54 -10.53% 5.13 5.19 4.57
May 1, 2024 5.23 0.26 5.23% 4.97 5.57 4.97
Apr 30, 2024 5.13 0.40 8.46% 4.73 5.15 4.65
Apr 29, 2024 4.68 0.05 1.08% 4.63 4.98 4.63
Apr 26, 2024 4.70 -0.38 -7.48% 5.08 5.11 4.68
Apr 25, 2024 5.15 -0.01 -0.19% 5.16 5.24 5.10
Apr 24, 2024 5.20 0.01 0.19% 5.19 5.30 5.10
Apr 23, 2024 5.18 0.00 0.00% 5.18 5.35 5.13
Apr 22, 2024 5.17 0.06 1.17% 5.11 5.24 5.05
Apr 19, 2024 5.13 -0.02 -0.39% 5.15 5.44 5.08
Apr 18, 2024 5.34 -0.04 -0.74% 5.38 5.47 5.18
Apr 17, 2024 5.37 0.09 1.70% 5.28 5.72 5.22
Apr 16, 2024 5.37 0.23 4.47% 5.14 5.44 5.13
Apr 15, 2024 5.23 -0.03 -0.57% 5.26 5.35 5.16
Apr 12, 2024 5.26 0.03 0.57% 5.23 5.51 5.12
Apr 11, 2024 5.42 0.17 3.24% 5.25 5.45 5.23

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lyra Therapeutics, Inc. Company profile

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).

Industry: Biotechnology & Medical Research (NEC)

480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US

People also watch

XRP/USD

0.60 Price
-3.710% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,482.63 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,406.02 Price
+0.430% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

65,678.05 Price
-3.700% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading